(NASDAQ: ADPT) Adaptive Biotechnologies's forecast annual revenue growth rate of 15.1% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.53%, and while it is forecast to beat the US market's average forecast revenue growth rate of 13.5%.
Adaptive Biotechnologies's revenue in 2026 is $276,976,000.On average, 10 Wall Street analysts forecast ADPT's revenue for 2026 to be $44,346,689,568, with the lowest ADPT revenue forecast at $42,010,789,288, and the highest ADPT revenue forecast at $46,305,335,024. On average, 10 Wall Street analysts forecast ADPT's revenue for 2027 to be $54,423,242,920, with the lowest ADPT revenue forecast at $51,195,789,401, and the highest ADPT revenue forecast at $57,299,618,479.
In 2028, ADPT is forecast to generate $65,217,350,346 in revenue, with the lowest revenue forecast at $60,938,202,766 and the highest revenue forecast at $69,895,310,169.